Executive SummaryLicensees in research-based alliances often offset the cost of these deals by supplanting large cash payments or equity purchases with the exchange of a valuable, non-cash asset. We examine some of these "quid pro quo" alliances that have taken place over the last year.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.